Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Imv Inc. (IMV.TO)

Imv Inc. (IMV.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 411,521
  • Shares Outstanding, K 66,482
  • Annual Sales, $ 568 K
  • Annual Income, $ -27,365 K
  • 60-Month Beta 2.14
  • Price/Sales 736.01
  • Price/Cash Flow N/A
  • Price/Book 18.43
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.63
  • Most Recent Earnings -0.13 on 06/30/20
  • Next Earnings Date 11/13/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.11
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +43.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.03 +18.29%
on 09/02/20
6.66 -10.66%
on 09/15/20
+0.36 (+6.44%)
since 08/24/20
3-Month
3.68 +61.68%
on 06/25/20
9.25 -35.68%
on 07/14/20
+2.01 (+51.02%)
since 06/24/20
52-Week
1.98 +200.51%
on 03/23/20
9.25 -35.68%
on 07/14/20
+1.90 (+46.91%)
since 09/24/19

Most Recent Stories

More News
IMV CEO to Participate at the Vaccines Panel of the Sachs Associates 20th Annual Biotech in Europe Forum

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious diseases, today announced that company's Chief...

IMV.TO : 5.95 (-3.88%)
Baculoviral IAP Repeat Containing Protein 5 Market Size 2020: An Introduction, COVID-19 Impact on Industry, Market Status, Future Forecast Indicates Impressive Growth Rate up to 2026

A recent report provides crucial insights along with application based and forecast information in the Global Baculoviral IAP Repeat Containing Protein 5 Market. The report provides a comprehensive analysis...

IMV.TO : 5.95 (-3.88%)
STML : 11.83 (-1.42%)
IMV to Participate at Four Upcoming Investor Conferences

IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today...

IMV.TO : 5.95 (-3.88%)
United States Baculoviral IAP Repeat Containing Protein 5 Market 2020 Research Report With COVID-19 Update, Growth Strategy and Industry Development to 2026

The report provides rational insights along with historical and forecast data to aid in better understanding of the Global United States Baculoviral IAP Repeat Containing Protein 5 Market. The report provides...

IMV.TO : 5.95 (-3.88%)
MFAC : 10.30 (+0.49%)
STML : 11.83 (-1.42%)
IMV Inc. Announces Second Quarter 2020 Financial Results

IMV Inc. (the "Company" or "IMV") (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today...

IMV.TO : 5.95 (-3.88%)
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that Canadian government...

IMV.TO : 5.95 (-3.88%)
IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020

IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious diseases...

IMV.TO : 5.95 (-3.88%)
IMV Files Preliminary Base Shelf Prospectus to Replace Expiring Base Shelf Prospectus

IMV Inc. ("IMV" or the "Company") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases,...

IMV.TO : 5.95 (-3.88%)
IMV Announces Leading Independent Proxy Advisory Firms Recommend Shareholders Vote FOR All Resolutions at Upcoming Annual and Special Meeting

IMV Inc. ("IMV" or the "Company") (Nasdaq: IMV; TSX: IMV), is pleased to announce that Institutional Shareholder Services Inc. ("ISS") and Glass, Lewis & Co., LLC ("Glass Lewis"), have recommended that...

IMV.TO : 5.95 (-3.88%)
IMV to Present at Raymond James' Human Health Innovation Conference

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today announced that company...

IMV.TO : 5.95 (-3.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 6.38
1st Resistance Point 6.16
Last Price 5.95
1st Support Level 5.67
2nd Support Level 5.40

See More

52-Week High 9.25
Fibonacci 61.8% 6.47
Last Price 5.95
Fibonacci 50% 5.61
Fibonacci 38.2% 4.76
52-Week Low 1.98

See More

Business Summary

IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar